Bone marrow-derived endothelial progenitor cells (EPCs) originate from haematopoietic stem cells in bone marrow and migrate into the peripheral circulation to promote endothelial repair and neovascularization. The number of circulating progenitor cells is reduced in patients with cardiovascular risk factor. The aim of our study was to determine the number of these cells in healthy patients and to evaluate the effect of Vardenfil, a phosphodiesterases-5 (PDE-5) inhibitor, in the number of circulating EPCs. In our study, we found a significant increase in the number of these cells after the drug administration.
Introduction
Circulating endothelial progenitor cells (EPCs) originate from haematopoietic stem cells in bone marrow, migrate into peripheral circulation, home to sites of neovascularization and differentiate into mature endothelial cells. In this way, EPCs contribute to neovascularization and to ongoing endothelial repair. 1 The mobilization of stem cells from the bone marrow is dependent on local secretion of metalloproteinase-9 (MMP-9) by the haematopoietic and stromal compartments of the bone marrow, thus resulting in releasing of soluble kit ligand. This process allows the transfer of endothelial and progenitor cells (PCs) from the quiescent to the proliferative niche. A recent study on mice suggested the essential role of endothelial nitric oxide synthase (eNOS), which produces NO from L-arginine, for the functional activity of haematopoietic stem cells and PCs. This study also demonstrated that nitric oxide (NO) acts primarily in a paracrine manner to induce an increase in the number of circulating EPCs, and that a lack of e-NOS induces defective haematopoietic recovery and PC mobilization. 2, 3 A decrease in the number of circulating EPCs has been demonstrated both in patients with overt cardiovascular risk factors and with erectile dysfunction, and in all patients with an endothelial dysfunction. 4 Selective phosphodiesterases-5 (PDE-5) inhibitors are widely used drugs for the treatment of erectile dysfunction, given that PDE5 is thought to be responsible of penis detumescence. PDE5 is the predominant isoenzyme of the PDE family in the corpora cavernosa of the penis, but its expression has been demonstrated in other organs such as smooth muscle, skeletal muscle, brain and kidney. Nitric oxide acts by increasing the activity of guanylyl cyclases, which increases the production of cyclic guanosine monophosphate (cGMP) and PDE5 inhibitors block the breakdown of cGMP.
A recent mice model suggested an effect of PDE-5 inhibitors not only in the erectile endothelium of the corpora cavernosa but also in other organs. Chronic administration of a PDE-5 inhibitor, DA-5819, induced haematological and bone marrow modifications with increase in lymphomonocytic component count and in bone marrow density, pointed out by a decrease in adipose tissue percentage. 6 However, the effect on EPCs is not known even if EPCs are a subset of the lymphomonocyte component of the peripheral circulation.
In this study, we evaluated the possible effect of Vardenafil, a PDE-5 inhibitor, on the number of PCs in the peripheral circulation.
Patients and methods
After approval by local ethics committee of the University of Padova, 10 healthy young men (2372 y) without cardiovascular risk factors were enrolled in this study. Blood samples were evaluated by flow cytometry, as described previously. 7 Briefly, analysis was performed on 150 ml of peripheral blood incubated with fluorescein isothiocyanate-labelled monoclonal antibodies against human CD34 (Becton Dickinson) and allophycocyaninlabelled monoclonal antibodies against human AC133 (Miltenyi Biotec); then, cells were lysed in NH 4 Cl lysis buffer, washed twice with PBS 1% FCS and then analysed by flow cytometry. Forward and side scatter gates were set to include all viable mononuclear cells; 500 000 events were acquired into these gates (Figure 1 ). Specificity of staining was confirmed using equal concentrations of isotype-matched control mAbs. Cells were scored using a FACSCalibur analyzer (Becton Dickinson Immunocytometry Systems, San Jose, California, USA), and data processed using the CellQuest software programs (Becton Dickinson Immunocytometry Systems). Double positivity for CD34 and AC133 allowed us to identify circulating PCs (Figure 1 ). Before applying flow cytometry analysis on the patients, 10 control samples were studied in triplicate, on different days, and at different hours of the day to validate the test. These data confirmed the validity of the analysis and no significant intraindividual variability was found. Patients were randomly allocated to two groups. The first group (five patients) received Vardenafil 20 mg at first visit and placebo 1 week later. The second group (five patients) received placebo at first visit and Vardenafil 20 mg 1 week later. Evaluation of PC numbers was performed in all cases at baseline, and 2 and 4 h after the oral administration.
The percentage of PC was calculated by the number of double positive events divided by the denominator ( ¼ total events). The total number of PCs per volume was subsequently calculated by multiplication of the PC percentages and the leucocyte count obtained from our haematology laboratory. Data are expressed as mean7s.d. Com- 
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Results
There was no significant intraindividual difference in PC concentration at baseline between the first (Figure 2) . No modifications were seen at 2 h after the administration of Vardenafil. The mean increase after Vardenafil administration was 795.77176.7 PCs/ml, with a percentage increase of 44.1716.5%.
Discussion
The present study shows for the first time that in humans a PDE-5 inhibitor, Vardenafil, increases circulating PCs. This effect seems to be acutely determined (4 h) after a single dose of Vardenafil in healthy young men. PDE-5 are widely expressed in humans also among male nonreproductive tissues, 5 but, at present, there are no data on specific expression of this enzyme in the bone marrow. It has been demonstrated that a PDE-5 inhibitor, DA-5819, induces haematological and bone marrow changes in mice, 6 suggesting a role of this class of drugs in these tissues, and thus also in humans. Further studies are needed to clarify the mechanism by which Vardenafil is able to increase circulating PCs, but two different hypotheses may be considered: EPCs emerge from the bone marrow or they differentiate from circulating haematopoietic cells. In the first case, PDE-5 inhibitors could magnify the cGMP, probably induced by the NO present in the bone marrow microenvironment. 3 Alternatively, an involvement of PDE-5 inhibitors could be hypothesized in the signalling pathway leading to PCs activation and mobilization on circulating haematopoietic cells not yet differentiated, and thus able to become PCs double positive for CD34 and AC133.
The finding that Vardenafil administration produces an increase of circulating PCs, even if from an unclear origin, may have important implications for the potential role of PDE-5 inhibitors in the prevention and progression of cardiovascular diseases. 8 The clinical significance of our results is not plain, and further studies are needed to clarify the relationship between the number of circulating EPCs and their physiopathological significance, considering the role of these cells in repairing endothelial injury, but also in neovascularization, and thus in oncologic situations. 
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